In an adult undergoing corneal transplantation, what is the recommended duration of prophylactic oral acyclovir, and how should it be adjusted for a history of recurrent herpes simplex virus keratitis or impaired renal function?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 6, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Duration of Acyclovir After Corneal Transplantation

For patients undergoing corneal transplantation for herpes simplex keratitis, prophylactic oral acyclovir should be continued for a minimum of 12 months postoperatively at a dose of 400 mg twice daily, with strong consideration for indefinite continuation in patients with a history of recurrent HSV keratitis. 1, 2, 3, 4

Standard Prophylactic Regimen

Dosing and Duration

  • Oral acyclovir 400 mg twice daily for at least 12 months is the evidence-based standard regimen following penetrating keratoplasty for HSV keratitis 3, 4
  • Alternative oral antivirals include valacyclovir 500 mg 2-3 times daily or famciclovir 250 mg twice daily, though these are extrapolated from acute treatment guidelines rather than post-transplant prophylaxis studies 5

Evidence Supporting Extended Prophylaxis

  • Prophylactic acyclovir reduces HSV recurrence risk by approximately 71% (RR 0.29,95% CI 0.13-0.64), preventing approximately 23 cases of recurrence per 100 corneal grafts 6
  • Graft failure risk is reduced by 60% (RR 0.40,95% CI 0.16-0.97), preventing approximately 13 graft failures per 100 operations 6
  • Studies demonstrate 0-8.3% recurrence rates with prophylaxis versus 33-50% without prophylaxis over 16-30 months of follow-up 1, 2, 3, 4

Risk-Stratified Approach

High-Risk Patients (History of Recurrent HSV Keratitis)

  • Consider indefinite prophylaxis beyond 12 months in patients with multiple prior HSV episodes or those who underwent transplantation for necrotizing keratitis with perforation 3
  • Recurrences may develop after cessation of acyclovir, particularly in high-risk patients (28.6% recurrence rate in necrotizing keratitis patients after stopping prophylaxis) 3
  • One study documented that 2 of 3 recurrences occurred specifically after withdrawal of acyclovir therapy at one year 3

Standard-Risk Patients

  • Minimum 12 months of prophylaxis is appropriate for patients with corneal scarring without perforation and no history of frequent recurrences 3, 4
  • After 12 months, consider tapering with close monitoring rather than abrupt cessation 3

Renal Function Adjustments

Dose Modifications

  • Acyclovir requires dose adjustment in renal impairment due to renal excretion 5
  • For valacyclovir (if used as alternative), renal dosing adjustments are mandatory in patients with impaired creatinine clearance 5
  • Monitor renal function periodically during long-term prophylaxis, particularly in elderly patients or those with baseline renal compromise 7

Specific Considerations

  • The kidney transplant literature provides guidance: reduce immunosuppression temporarily if systemic HSV infection develops, though this principle applies differently to corneal transplant patients who are not systemically immunosuppressed 7

Critical Management Principles

Contraindications During Prophylaxis

  • Topical corticosteroids must be used cautiously and only after epithelial healing is complete, as they potentiate HSV replication 8, 9, 5
  • Never use corticosteroids for active epithelial disease even while on prophylactic antivirals 8, 9

Monitoring Requirements

  • Schedule follow-up within 1 week initially, then regularly throughout the first year 8, 9
  • Perform visual acuity measurement and slit-lamp biomicroscopy at each visit to detect early recurrence 8, 9
  • Monitor for signs of graft rejection, which occurred in 15.8% of prophylaxis patients but was successfully treated medically 3

Common Pitfalls to Avoid

Treatment Errors

  • Do not use oral antivirals as monotherapy for active epithelial keratitis if it develops during prophylaxis; combination with topical antivirals is mandatory 8, 9, 5
  • Do not abruptly discontinue prophylaxis at 12 months in high-risk patients without careful consideration of extended therapy 3
  • Do not assume prophylaxis provides complete protection; breakthrough infections can occur (8.3% even while on therapy) 3

Safety Considerations

  • No serious adverse effects requiring discontinuation were reported in the included studies 6
  • Long-term low-dose acyclovir (400 mg/day) appears well-tolerated for at least 12 months 3

References

Research

Systemic acyclovir and penetrating keratoplasty for herpes simplex keratitis.

Documenta ophthalmologica. Advances in ophthalmology, 1992

Research

Oral acyclovir after penetrating keratoplasty for herpes simplex keratitis.

Archives of ophthalmology (Chicago, Ill. : 1960), 1999

Guideline

Valacyclovir Dosing for Herpes Simplex Keratitis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Treatment of HSV Epithelial Keratitis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Herpes with Ophthalmic Involvement

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.